Literature DB >> 22665067

Akt1 inhibits homologous recombination in Brca1-deficient cells by blocking the Chk1-Rad51 pathway.

Y Jia1, W Song, F Zhang, J Yan, Q Yang.   

Abstract

Brca1 deficiency leads to the development of breast cancer. We previously found that Brca1 deficiency activates the Akt oncogenic pathway. Reduced expression of Brca1 was highly correlated with increased activated Akt in human breast cancer samples. Furthermore, activation of Akt1 was involved in Brca1-deficiency-mediated tumorigenesis in mice. Defective homologous recombination (HR) is thought to be a major contributor to tumorigenesis in Brca1 deficiency. Here, we show that Akt1 promotes chromosome instability in Brca1-deficent cells. DNA breaks in Brca1-deficent cells are aberrantly joined into complex chromosome rearrangements by a process dependent on Akt1. Depletion of Akt1 increases HR in Brca1-mutant cells, which is rescued by expression of wild-type, but not mutant Akt1 with deletion of Brca1-binding domain. Mechanistically, activated Akt1 in Brca1-deficient cells impairs Chk1 nuclear localization and subsequently disrupts interaction of Chk1 and Rad51 leading to HR defects. Our results indicate that Brca1 deficiency might activate Akt1 contributing to tumorigenesis through regulation of the Chk1-Rad51 signaling.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22665067      PMCID: PMC3700338          DOI: 10.1038/onc.2012.211

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  25 in total

1.  53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks.

Authors:  Samuel F Bunting; Elsa Callén; Nancy Wong; Hua-Tang Chen; Federica Polato; Amanda Gunn; Anne Bothmer; Niklas Feldhahn; Oscar Fernandez-Capetillo; Liu Cao; Xiaoling Xu; Chu-Xia Deng; Toren Finkel; Michel Nussenzweig; Jeremy M Stark; André Nussenzweig
Journal:  Cell       Date:  2010-04-01       Impact factor: 41.582

2.  Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair.

Authors:  Koji Nakanishi; Yun-Gui Yang; Andrew J Pierce; Toshiyasu Taniguchi; Martin Digweed; Alan D D'Andrea; Zhao-Qi Wang; Maria Jasin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-13       Impact factor: 11.205

Review 3.  Activation of AKT kinases in cancer: implications for therapeutic targeting.

Authors:  Alfonso Bellacosa; C Chandra Kumar; Antonio Di Cristofano; Joseph Robert Testa
Journal:  Adv Cancer Res       Date:  2005       Impact factor: 6.242

4.  The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair.

Authors:  Claus Storgaard Sørensen; Lasse Tengbjerg Hansen; Jaroslaw Dziegielewski; Randi G Syljuåsen; Cecilia Lundin; Jiri Bartek; Thomas Helleday
Journal:  Nat Cell Biol       Date:  2005-01-23       Impact factor: 28.824

5.  Targeting the Akt/mTOR pathway in Brca1-deficient cancers.

Authors:  T Xiang; Y Jia; D Sherris; S Li; H Wang; D Lu; Q Yang
Journal:  Oncogene       Date:  2011-01-17       Impact factor: 9.867

6.  Negative Regulation of AKT Activation by BRCA1.

Authors:  Tao Xiang; Amiko Ohashi; Yuping Huang; Tej K Pandita; Thomas Ludwig; Simon N Powell; Qin Yang
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

7.  AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51.

Authors:  Isabelle Plo; Corentin Laulier; Laurent Gauthier; Fabienne Lebrun; Fabien Calvo; Bernard S Lopez
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

8.  53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.

Authors:  Peter Bouwman; Amal Aly; Jose M Escandell; Mark Pieterse; Jirina Bartkova; Hanneke van der Gulden; Sanne Hiddingh; Maria Thanasoula; Atul Kulkarni; Qifeng Yang; Bruce G Haffty; Johanna Tommiska; Carl Blomqvist; Ronny Drapkin; David J Adams; Heli Nevanlinna; Jiri Bartek; Madalena Tarsounas; Shridar Ganesan; Jos Jonkers
Journal:  Nat Struct Mol Biol       Date:  2010-05-09       Impact factor: 15.369

9.  Telomere recombination requires the MUS81 endonuclease.

Authors:  Sicong Zeng; Tao Xiang; Tej K Pandita; Ignacio Gonzalez-Suarez; Susana Gonzalo; Curtis C Harris; Qin Yang
Journal:  Nat Cell Biol       Date:  2009-04-12       Impact factor: 28.824

Review 10.  BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution.

Authors:  Chu-Xia Deng
Journal:  Nucleic Acids Res       Date:  2006-03-06       Impact factor: 16.971

View more
  19 in total

1.  RAD51 regulates CHK1 stability via autophagy to promote cell growth in esophageal squamous carcinoma cells.

Authors:  Xinyi Zhu; Qiuhui Pan; Nan Huang; Jianchun Wu; Ni Zhen; Fenyong Sun; Zhi Li; Qingyuan Yang
Journal:  Tumour Biol       Date:  2016-10-14

Review 2.  Mapping the protein-protein and genetic interactions of cancer to guide precision medicine.

Authors:  Mehdi Bouhaddou; Manon Eckhardt; Zun Zar Chi Naing; Minkyu Kim; Trey Ideker; Nevan J Krogan
Journal:  Curr Opin Genet Dev       Date:  2019-07-06       Impact factor: 5.578

Review 3.  Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer.

Authors:  Tzu-Ting Huang; Erika J Lampert; Cynthia Coots; Jung-Min Lee
Journal:  Cancer Treat Rev       Date:  2020-04-10       Impact factor: 12.111

4.  Nitroglycerin-induced downregulation of AKT- and ERK1/2-mediated radiation-sensitive 52 expression to enhance pemetrexed-induced cytotoxicity in human lung cancer cells.

Authors:  Jen-Chung Ko; Jyh-Cheng Chen; Pei-Yu Tseng; Jou-Min Hsieh; Chen-Shan Chiang; Li-Ling Liu; Chin-Cheng Chien; I-Hsiang Huang; Yun-Wei Lin
Journal:  Toxicol Res (Camb)       Date:  2022-03-26       Impact factor: 2.680

Review 5.  Role of AKT signaling in DNA repair and clinical response to cancer therapy.

Authors:  Qun Liu; Kristen M Turner; W K Alfred Yung; Kexin Chen; Wei Zhang
Journal:  Neuro Oncol       Date:  2014-05-07       Impact factor: 12.300

6.  The EMSY threonine 207 phospho-site is required for EMSYdriven suppression of DNA damage repair.

Authors:  Petar Jelinic; Laura A Eccles; Jill Tseng; Paulina Cybulska; Monicka Wielgos; Simon N Powell; Douglas A Levine
Journal:  Oncotarget       Date:  2017-02-21

7.  Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers.

Authors:  Chong-kui Sun; Fan Zhang; Tao Xiang; Qianming Chen; Tej K Pandita; Yuping Huang; Mickey C T Hu; Qin Yang
Journal:  Oncotarget       Date:  2014-05-30

Review 8.  Targeting the AKT pathway: Repositioning HIV protease inhibitors as radiosensitizers.

Authors:  Jayant S Goda; Tejaswini Pachpor; Trinanjan Basu; Supriya Chopra; Vikram Gota
Journal:  Indian J Med Res       Date:  2016-02       Impact factor: 2.375

9.  Cell Killing Mechanisms and Impact on Gene Expression by Gemcitabine and 212Pb-Trastuzumab Treatment in a Disseminated i.p. Tumor Model.

Authors:  Kwon Joong Yong; Diane E Milenic; Kwamena E Baidoo; Martin W Brechbiel
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

10.  Akt1 Stimulates Homologous Recombination Repair of DNA Double-Strand Breaks in a Rad51-Dependent Manner.

Authors:  Katharina Mueck; Simone Rebholz; Mozhgan Dehghan Harati; H Peter Rodemann; Mahmoud Toulany
Journal:  Int J Mol Sci       Date:  2017-11-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.